Endothelin-dependent vasoconstrictor activity in metabolically healthy and unhealthy obese patients

Le résumé fourni par la source

Therefore, we investigated oxidative stress levels in AMI patients with lipophilic atorvastatin or hydrophilic pravastatin.Methods and results: The study population included a prospective, randomized, open-label, study in AMI patients within ALPS-AMI study.Patients that have undergone successful percutaneous coronary intervention will be randomly allocated to receive either atorvastatin or pravastatin with the treatment goal of lowering their low-density lipoprotein-cholesterol level below 100 mg/dl for 2 years.Diacron-reactive oxygen metabolite (dROM) and biological antioxidant potential (BAP) levels were measured in AMI patients with lipophilic (atorvastatin, n = 38) and hydrophilic (pravastatin, n = 36) statin therapy on admission (dROM: 395.5 ± 37.5 vs. 392.1 ± 35.6 Carratelli units (U.Carr) (p = 0.37), BAP: 2756.3 ± 75.2 vs. 2849.1 ± 71.6 mmol/l (p = 0.39), respectively) and 6, 12, and 24 months (24 months: dROM: 374.5 ± 41.5 vs. 381.1 ± 37.6 U. Carr (p = 0.28), BAP: 2957.3 ± 135.9 vs. 2941.5 ± 121.3 mmol/l (p = 0.48), respectively).Conclusion: This is the first clinical trial to compare the effects of lipophilic and hydrophilic statin therapy on oxidative stress levels and no difference was noted in oxidative stress levels between lipophilic and hydrophilic statin therapy in patients with AMI during the follow-up period.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.